Steven M Firestine & Troy Lister 
Antibiotic Drug Discovery 
New Targets and Molecular Entities

Recent years have seen a resurgence of antibiotic drug discovery. This book brings together the relevant information to assess the state-of-the-art. It identifies and elaborates the most recent and compelling strategies for antibiotic drug discovery with a primary focus on new targets, mechanisms and molecular entities. Addressing the need for continued investment in antibiotic drug development, the book provides a point of reference for the rapidly expanding infectious disease research community.

In addition to its attention on new targets, the book focusses on the medicinal chemistry and chemistry of the targets. Within this framework, chapters from leading researchers in academia and industry address findings in important areas such as biofilm production, narrow spectrum antibiotics and novel antibacterials from previously uncultured soil bacteria.

This book will be a useful resource for postgraduate students and researchers in medicinal chemistry wishing to understand the latest approaches to antibiotic drug discovery.

Table of Content

Treatment of Clostridium difficile Infections; Targeting Purine Biosynthesis for Antibacterial Drug Design; Inhibitors of Biofilm Production; Narrow Spectrum Antibacterial Agents; The LPS Transport Pathway: A New Target for the Development of Gram-Negative Antibiotics; The Discovery of Teixobactin; Emerging Targets in Anti-Tubercular Drug Design; Antibacterial Leads Targeting Isoprenoid Biosynthesis

About the author

Steven M. Firestine is an Associate Professor of Medicinal Chemistry at the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University. He received a B.S. with honors in chemistry from the University of Michigan and a Ph D in Medicinal Chemistry from Purdue University. Dr. Firestine conducted postdoctoral research in the laboratory of Dr. Stephen J. Benkovic before joining the medicinal chemistry faculty at Duquesne University. In 2005 he moved to Wayne State University. Dr. Firestine maintains an active research program focused in the area of anti-infective drug design. To date, he has authored more than 40 articles in peer-reviewed research journals and presented more than 75 research abstracts and seminars. Dr. Firestine is an active reviewer for the NIH and the MRC.  He serves on the editorial board of ACS Combinatorial Sciences and is a reviewer for numerous scientific journals.
Troy Lister, Ph D, is Head of Chemistry at Spero Therapeutics in Cambridge, MA. Dr. Lister previously held roles as Team Leader of Infection Chemistry at Astra Zeneca and Investigator III in Global Discovery Chemistry at the Novartis Institute for Bio Medical Research. He has lead numerous discovery programs searching for novel agents targeting bacterial and viral pathogens including multidrug resistant Gram negative and Gram positive bacteria, hepatitis C virus, human rhinovirus, respiratory syncytial virus, ebola virus and human enterovirus. Dr. Lister has led programs from the earliest stages of target selection and high throughput screening, through lead identification and optimization, to candidate selection and IND enablement. He is an author of 15 peer review publications, has extensive experience in natural product chemistry and is a member of the American Chemical Society. Dr. Lister received his B.Tech, B.S. and Ph D degrees from Flinders University in Adelaide, Australia, and completed a post-doctoral fellowship at The Scripps Research Institute in La Jolla, California with Professoer K.C. Nicolaou.